G protein-coupled receptor kinase 2

G protein-coupled receptor kinase 2
Name	G protein-coupled receptor kinase 2
Other names	GRK2
Uniprot	P25098
Length	689–716 aa
Organism	Homo sapiens

G protein-coupled receptor kinase 2 is a serine/threonine kinase that phosphorylates activated G protein–coupled receptors, promoting receptor desensitization and internalization. Identified in studies involving George D. Snell-era genetics and later molecular cloning during the era of Michael S. Brown and Joseph L. Goldstein's expansion of signal transduction research, the kinase has been characterized biochemically and structurally through collaborations among laboratories at institutions such as Harvard University, Stanford University, and the National Institutes of Health. GRK2 participates in pathways intersecting with signaling networks studied by researchers at the Max Planck Society and clinical groups at Mayo Clinic and Johns Hopkins Hospital.

Introduction

GRK2 belongs to the GRK family discovered amid efforts led by scientists in the 1980s comparable to projects at Cold Spring Harbor Laboratory and Laboratory of Molecular Biology (Cambridge). Early biochemical characterization involved methods developed by teams at Salk Institute and structural insights achieved with support from facilities like the European Molecular Biology Laboratory. GRK2 is encoded by ADRBK1 and is evolutionarily conserved across metazoans, with ortholog studies performed in organisms examined by researchers from University of California, Berkeley and University of Cambridge.

Structure and Domains

GRK2 comprises an N-terminal regulator of G protein signaling homology domain resembling RGS proteins examined by groups at Stanford University School of Medicine, a central catalytic domain homologous to the AGC kinase family characterized by researchers at University of Oxford, and a C-terminal pleckstrin homology (PH) domain that mediates membrane interactions with G protein βγ subunits and phospholipids. High-resolution structures were solved using techniques pioneered at Max Planck Institute for Biophysical Chemistry and beamlines at the European Synchrotron Radiation Facility, revealing conserved motifs similar to those described in kinases studied by investigators at Massachusetts Institute of Technology. The PH domain binds Gβγ subunits in manners comparable to interactions mapped in studies at University of California, San Francisco.

Function and Mechanism of Action

GRK2 phosphorylates activated G protein–coupled receptors on serine and threonine residues, facilitating recruitment of β-arrestin proteins first characterized by labs at Columbia University and University College London. This phosphorylation-dependent arrestin binding uncouples receptors from heterotrimeric G proteins and directs receptors into clathrin-mediated endocytosis, processes explored by researchers at Yale University and University of Pennsylvania. GRK2 also phosphorylates non-receptor substrates and scaffolds signaling complexes involving pathways investigated at University of Chicago and University of Michigan, linking to mitogen-activated protein kinase cascades studied by teams at Max Planck Institute for Molecular Genetics.

Regulation and Post-translational Modifications

GRK2 activity is regulated by interactions with Gβγ subunits and by phosphorylation by kinases such as Protein kinase A and Protein kinase C, whose regulatory roles were delineated at institutions like University of California, Los Angeles and University of Texas Southwestern Medical Center. GRK2 undergoes phosphorylation, ubiquitination directed by E3 ligases studied at Cold Spring Harbor Laboratory, and S-nitrosylation investigated by groups at University of North Carolina at Chapel Hill. Proteolytic cleavage by calpains under conditions analyzed by researchers at National Cancer Institute modulates levels of GRK2 in cellular models developed at Karolinska Institutet.

Physiological Roles and Tissue Distribution

GRK2 is widely expressed with abundant levels in heart tissue, vasculature, brain regions studied at Columbia University Medical Center, and immune cells profiled in studies at Imperial College London. In cardiomyocytes, GRK2 modulates β-adrenergic receptor signaling in pathways researched by teams at Cleveland Clinic and Duke University Medical Center, influencing contractility and remodeling. In the central nervous system, GRK2 regulates neurotransmitter receptors in manners investigated at Johns Hopkins University School of Medicine and contributes to inflammatory signaling in immune contexts examined at Pasteur Institute.

Clinical Significance and Disease Associations

Elevated GRK2 expression or activity correlates with heart failure cohorts characterized in clinical studies at Brigham and Women's Hospital and Mount Sinai Hospital, and with metabolic dysfunction in investigations at University of Cambridge Metabolic Research Laboratories. Altered GRK2 has been implicated in cancer progression in analyses published by teams at Memorial Sloan Kettering Cancer Center and in mood disorders in clinical neuroscience programs at National Institute of Mental Health. Genetic and biochemical perturbations of GRK2 affect outcomes in preclinical models studied at Scripps Research Institute and Fred Hutchinson Cancer Center.

Pharmacology and Therapeutic Targeting

GRK2 is a therapeutic target for small-molecule inhibitors and peptide-based strategies developed in collaborations among pharmaceutical firms like Pfizer and biotechnology groups associated with Genentech. Approaches include selective kinase inhibitors informed by structure-guided design from research at Novartis Institutes for BioMedical Research and biased signaling modulators explored by investigators at Eli Lilly and Company. Clinical translation efforts and trials have involved centers such as University Hospital Zürich and Cleveland Clinic Foundation, aiming to treat heart failure, metabolic disease, and cancer by modulating GRK2 activity.

Category:Kinases Category:Signal transduction proteins